Hamdy A. Azim
YOU?
Author Swipe
View article: Homologous Recombination Deficiency Testing in Women With Ovarian Cancer: An Egyptian Multicentre Study
Homologous Recombination Deficiency Testing in Women With Ovarian Cancer: An Egyptian Multicentre Study Open
View article: Social Determinants Associated With the Advanced-Stage Diagnosis of Breast Cancer
Social Determinants Associated With the Advanced-Stage Diagnosis of Breast Cancer Open
PURPOSE The majority of Egyptian patients with breast cancer (BC) present at advanced stages. We examined the sociodemographic and clinical factors associated with late presentation of BC. METHODS A retrospective cohort study was conducted…
View article: Correlation of TROP2 expression with clinico-pathological features and outcomes in HR+/HER2− breast cancer receiving neoadjuvant chemotherapy
Correlation of TROP2 expression with clinico-pathological features and outcomes in HR+/HER2− breast cancer receiving neoadjuvant chemotherapy Open
Background Limited data exists about the associations between TROP2 protein, clinico-pathological characteristics, and outcomes in patients with an early HR+/HER2- breast cancer (BC). Patients and Methods TROP2 membranous expression was as…
View article: 280P Key performance indicators (KPIs) of screening via clinical breast examination (CBE): A pooled analysis of 9.3 million screened women
280P Key performance indicators (KPIs) of screening via clinical breast examination (CBE): A pooled analysis of 9.3 million screened women Open
View article: Final Results of RIGHT Choice: Ribociclib Plus Endocrine Therapy Versus Combination Chemotherapy in Premenopausal Women With Clinically Aggressive Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer
Final Results of RIGHT Choice: Ribociclib Plus Endocrine Therapy Versus Combination Chemotherapy in Premenopausal Women With Clinically Aggressive Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer Open
PURPOSE A head-to-head comparison of efficacy between a cyclin-dependent kinase 4/6 inhibitor plus endocrine therapy (ET) versus combination chemotherapy (CT) has never been reported in patients with clinically aggressive hormone receptor–…
View article: Equitable inclusion of diverse populations in oncology clinical trials: deterrents and drivers
Equitable inclusion of diverse populations in oncology clinical trials: deterrents and drivers Open
View article: Egyptian Society of Liver Cancer Recommendation Guidelines for the Management of Hepatocellular Carcinoma [Corrigendum]
Egyptian Society of Liver Cancer Recommendation Guidelines for the Management of Hepatocellular Carcinoma [Corrigendum] Open
[This corrects the article DOI: 10.2147/JHC.S404424.].
View article: 456P Quality of life (QOL) analysis from the phase II RIGHT choice study of first-line ribociclib (RIB) + endocrine therapy (ET) vs combination chemotherapy (combo CT) in aggressive HR+/HER2− advanced breast cancer (ABC)
456P Quality of life (QOL) analysis from the phase II RIGHT choice study of first-line ribociclib (RIB) + endocrine therapy (ET) vs combination chemotherapy (combo CT) in aggressive HR+/HER2− advanced breast cancer (ABC) Open
View article: 1759MO Clinical breast examination for early diagnosis of breast cancer: An Egyptian nationwide study
1759MO Clinical breast examination for early diagnosis of breast cancer: An Egyptian nationwide study Open
View article: The Landscape of BRCA Mutations among Egyptian Women with Breast Cancer
The Landscape of BRCA Mutations among Egyptian Women with Breast Cancer Open
View article: Egyptian Society of Liver Cancer Recommendation Guidelines for the Management of Hepatocellular Carcinoma
Egyptian Society of Liver Cancer Recommendation Guidelines for the Management of Hepatocellular Carcinoma Open
Globally, hepatocellular carcinoma (HCC) is the fourth most common cause of death from cancer. The prevalence of this pathology, which has been on the rise in the last 30 years, has been predicted to continue increasing. HCC is the most co…
View article: The social determinants associated with the advanced stage diagnosis of breast cancer in Egypt
The social determinants associated with the advanced stage diagnosis of breast cancer in Egypt Open
Background Majority of Egyptian breast cancer (BC) patients present at advanced stages. We examined the sociodemographic and clinical factors associated with late presentation of BC. Methods This is a retrospective cohort study of patients…
View article: The social determinants associated with the advanced stage diagnosis of breast cancer in Egypt in the previous ten years: a single-center quantitative retrospective cohort study
The social determinants associated with the advanced stage diagnosis of breast cancer in Egypt in the previous ten years: a single-center quantitative retrospective cohort study Open
Population Medicine considers the following types of articles:• Research Papers -reports of data from original research or secondary dataset analyses.• Review Papers -comprehensive, authoritative, reviews within the journal's scope.These i…
View article: Clinicopathologic Features of Breast Cancer in Egypt—Contemporary Profile and Future Needs: A Systematic Review and Meta-Analysis
Clinicopathologic Features of Breast Cancer in Egypt—Contemporary Profile and Future Needs: A Systematic Review and Meta-Analysis Open
PURPOSE Breast cancer (BC) is the most common cancer among Egyptian females. No current national cancer database is available in Egypt to provide reliable data on the specific clinicopathologic features of BC in this population. Herein, we…
View article: Real-world treatment patterns and clinical outcomes in patients with stage III non-small cell lung cancer: results of KINDLE-Egypt cohort
Real-world treatment patterns and clinical outcomes in patients with stage III non-small cell lung cancer: results of KINDLE-Egypt cohort Open
Background: Stage III non-small cell lung cancer (NSCLC) being highly heterogeneous requires multimodal therapeutic strategies for optimal management. We present findings on treatment patterns and their associated survival outcomes in pati…
View article: Frontline Management of Advanced Epithelial Ovarian Cancer: AComprehensive Statement by the Africa Middle East Cancer Inter-group[AMCI]
Frontline Management of Advanced Epithelial Ovarian Cancer: AComprehensive Statement by the Africa Middle East Cancer Inter-group[AMCI] Open
Worldwide, ovarian cancer (OC) is one of the leading causes of cancer-related death among women. Despite the recent progress in the treatment of advanced OC, oncologists in many parts of the world still face several difficulties and constr…
View article: 205P Pooled exploratory analysis of survival in patients (pts) with HR+/HER2- advanced breast cancer (ABC) and visceral metastases (mets) treated with ribociclib (RIB) + endocrine therapy (ET) in the MONALEESA (ML) trials
205P Pooled exploratory analysis of survival in patients (pts) with HR+/HER2- advanced breast cancer (ABC) and visceral metastases (mets) treated with ribociclib (RIB) + endocrine therapy (ET) in the MONALEESA (ML) trials Open
View article: Safety and efficacy of adjuvant subcutaneous trastuzumab in human epidermal growth factor receptor 2-positive early breast cancer: Final results of the SafeHER study
Safety and efficacy of adjuvant subcutaneous trastuzumab in human epidermal growth factor receptor 2-positive early breast cancer: Final results of the SafeHER study Open
The 5-year follow-up analysis of the SafeHER trial demonstrating that SC trastuzumab has an acceptable safety profile, including cardiac toxicity, and efficacy for the treatment of HER2-positive EBC with and without chemotherapy, correspon…
View article: Correction to: Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population
Correction to: Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population Open
View article: Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population
Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population Open
View article: Breast-Gynaecological & Immuno-Oncology International Cancer Conference (BGICC) Consensus and Recommendations for the Management of Triple-Negative Breast Cancer
Breast-Gynaecological & Immuno-Oncology International Cancer Conference (BGICC) Consensus and Recommendations for the Management of Triple-Negative Breast Cancer Open
Background: The management of patients with triple-negative breast cancer (TNBC) is challenging with several controversies and unmet needs. During the 12th Breast-Gynaecological & Immuno-oncology International Cancer Conference (BGICC) Egy…
View article: 5-year follow-up of the safety, tolerability and efficacy of subcutaneous trastuzumab for the adjuvant treatment of HER2-positive early breast cancer. Results from the SafeHER Phase III trial
5-year follow-up of the safety, tolerability and efficacy of subcutaneous trastuzumab for the adjuvant treatment of HER2-positive early breast cancer. Results from the SafeHER Phase III trial Open
View article: Integrating PARP inhibitors into the management of breast cancer: where are we?
Integrating PARP inhibitors into the management of breast cancer: where are we? Open
During the last 2 decades, extensive research has focused on the molecular functions of BRCA1 and BRCA2 genes. This has led to the development of Poly(ADP-ribose) polymerase inhibitors (PARPi), as effective target therapies, based on their…
View article: Ribociclib plus goserelin with hormonal therapy versus physician choice chemotherapy in pre-/perimenopausal patients with HR+, HER2– inoperable locally advanced breast cancer (ABC): RIGHT choice study
Ribociclib plus goserelin with hormonal therapy versus physician choice chemotherapy in pre-/perimenopausal patients with HR+, HER2– inoperable locally advanced breast cancer (ABC): RIGHT choice study Open
View article: Issue Information
Issue Information Open
The Breast Journal is a multidisciplinary publication with an equal partnership of different specialties and a focused approach toward enhancing our understanding of breast disease.The Breast Journal's editorial philosophy recognizes the i…
View article: OSSMAR: An Observational Study to Describe the Use of Sunitinib in Real-Life Practice for the Treatment of Metastatic Renal Cell Carcinoma
OSSMAR: An Observational Study to Describe the Use of Sunitinib in Real-Life Practice for the Treatment of Metastatic Renal Cell Carcinoma Open
PURPOSE Sunitinib offers improved efficacy for patients with metastatic renal cell carcinoma (mRCC). To provide better disease management in the Middle East, we studied its use in mRCC in real-life practice in this region. MATERIAL AND MET…
View article: Durable Response of Androgen Receptor-Positive Male Breast Cancer to Goserelin
Durable Response of Androgen Receptor-Positive Male Breast Cancer to Goserelin Open
The luteinizing hormone-releasing hormone/androgen receptor (LHRH/AR) pathway is a promising treatment target in a subgroup of female patients with triple-negative breast cancer (TNBC). However, very little is known about the efficacy of t…
View article: Sorafenib plus tegafur–uracil (UFT) versus sorafenib as first line systemic treatment for patients with advanced stage HCC: a Phase II trial (ESLC01 study)
Sorafenib plus tegafur–uracil (UFT) versus sorafenib as first line systemic treatment for patients with advanced stage HCC: a Phase II trial (ESLC01 study) Open
In patients with advanced HCC, adding UFT to sorafenib is feasible, but it did not improve efficacy outcome over sorafenib monotherapy.
View article: Ribociclib (RIBO) + letrozole (LET) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC) who received prior chemotherapy (CT) for advanced disease: Preliminary subgroup results from the phase IIIb CompLEEment-1 trial
Ribociclib (RIBO) + letrozole (LET) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC) who received prior chemotherapy (CT) for advanced disease: Preliminary subgroup results from the phase IIIb CompLEEment-1 trial Open
Background: CDK4/6 inhibitor RIBO is approved in combination with an aromatase inhibitor (AI) for HR+, HER2– ABC in postmenopausal women with no prior therapy for ABC, based on the MONALEESA-2 trial (Hortobagyi et al. NEJM 2016). Previous …
View article: Ribociclib (RIBO) + letrozole (LET) in premenopausal patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC) with no prior endocrine therapy (ET) for ABC: Preliminary subgroup results from the phase IIIb CompLEEment-1 trial
Ribociclib (RIBO) + letrozole (LET) in premenopausal patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC) with no prior endocrine therapy (ET) for ABC: Preliminary subgroup results from the phase IIIb CompLEEment-1 trial Open
Background: CDK4/6 inhibitor RIBO significantly improved progression-free survival in combination with ET versus placebo + ET in pre- and postmenopausal women with HR+, HER2– ABC and no prior therapy for advanced disease in the pivotal pha…